it’s hard not to root for a team trying to rescue sight and neurological development, a lot of the target market being kids
Just got to be patient as PYC will likely benefit from funding/deal flows bouncing off 5 year lows, with $1.4 trillion sitting on the sidelines, an approved FDA IND will attract some attention
After several years of heavy deal making, big pharmaceutical companies dialed back acquisitions more recently. They had bought many of the most attractive targets, and those that remained had gotten very expensive.The $88 billion in total deal value last year, involving 75 biopharma tie-ups of at least $100 million, was the lowest since 2017, Ernst & Young said. Yet by the end of last year, EY estimated, life-sciences companies had more than $1.4 trillion in cash and other capital they could use for deal making, up 11% from the previous year.
https://www.wsj.com/articles/pfizer-novartis-merck-executives-say-they-are-hunting-for-deals-again-11675907783
it’s hard not to root for a team trying to rescue sight and...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.020(1.74%) |
Mkt cap ! $659.0M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.19 | $1.13 | $187.3K | 162.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5698 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 938 | 1 |
View Market Depth
| Last trade - 16.10pm 19/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |